Electronic Brachytherapy for the Treatment of NMSC

Inclusion Criteria: * Patient has signed the informed consent form * Pathological diagnosis confirmed of squamous cell or basal cell carcinoma * Histopathological Grade: G1 (well differentiated), G2 (moderately differentiated), or Gx (Not assessed in report) * Clinical Staging Tis, T1, or T2 (Must be ≤ 4 cm in diameter) * One lesion is treated, or more than 1 lesion is treated with a minimum of a 5 mm gap between the edges of the lesion margins. Exclusion Criteria: * T2 \> 4 cm and T3 and T4 * American Joint Committee Staging for NMSC Stages III and IV * Histopathologic Grade 3 (poorly differentiated) or higher grade * Target area is adjacent to a burn scar * Target area is on the lip * Patient \< 50 years of age * Any prior definitive surgical resection of the cancer * Perineural invasion * Lesion depth \> 5mm on clinical assessment or as assessed by ultrasound or CT. * Patient is pregnant (pregnancy test required if standard of care). * Target area is prone to trauma. * Target area with compromised lymphatic or vascular drainage. * Participation in another investigational device or drug study concurrently. * Patient has undergone prior radiation therapy to this specific anatomic location. * Patient is receiving pharmacologic agent(s) at or around the time of the Radiation therapy that is/are known to produce skin reactions that will influence cosmesis grading during study. * Patient is receiving chemotherapeutic agent(s) Six (6) weeks before or six (6) weeks after radiation therapy. * Life expectancy less than five (5) years.